Kimia Farma (Persero) Tbk PT operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kimia Farma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Shandong Lukang Pharmaceutical
sales of 2.51 billion Chinese Renmimbi [US$377.51 million]
of which 67%
was Human Antibiotic),
ChangChun High New Technology Industries
(2.87 billion Chinese Renmimbi [US$433.06 million]
of which 81%
was Medication), and
Luye Pharma Group Limited
based in Singapore
(605.73 million Singapore Dollars [US$445.72 million]
of which 54%
was Oncology Drugs).
Kimia Farma (Persero) Tbk PT reported sales of 5.81 trillion Indonesian Rupiahs (US$428.89 million)
December of 2016.
increase of 19.6%
versus 2015, when the company's sales were 4.86 trillion Indonesian Rupiahs.
Sales at Kimia Farma (Persero) Tbk PT have increased during each of the previous five years
(and since 2011, sales have increased a total of 67%).
Sales of Distribution saw an increase
32.4% in 2016, from
1.85 trillion Indonesian Rupiahs to 2.45 trillion Indonesian Rupiahs.
Not all segments of Kimia Farma (Persero) Tbk PT experienced an increase in sales in 2016:
sales of Other fell 3.3% to 87.40 billion Indonesian Rupiahs.
(However, this segment's sales were only a very small portion of the company's overall sales).